3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
5
von Hippel-Lindau Disease
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
3-Iodobenzylguanidine
8
anlotinib
4
Temozolomide
4
lutetium Lu 177 dotatate
3
Phenoxybenzamine
3
Everolimus
3
pegfilgrastim
2
cabozantinib
2
Granulocyte Colony-Stimulating Factor
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Adrenalectomy
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
vandetanib
1
temsirolimus
1
pentetreotide
1
penpulimab
1
pembrolizumab
1
olaparib
1
lenvatinib
1
lanreotide
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pheochromocytoma
×
belzutifan
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled